Abstract
We present the case of a 59-year-old female who developed rheumatoid arthritis in 2007. Right total knee arthroplasty (TKA) was performed in 2008. Although she was treated with methotrexate (MTX) after the operation, this treatment was insufficient. Infliximab (IFX) was introduced in 2001, and she achieved clinical remission. Left TKA was performed in October 2014. Because active synovitis was not detected by ultrasound after the operation, IFX was discontinued. She had been treated with MTX 8 mg weekly. However, arthralgia of the bilateral knees developed in March 2015. Ultrasound showed synovial hypertrophy with vascular signals representing postoperative residual synovitis. She was given certolizumab pegol. According to ultrasound, the synovitis had improved after 3 months.
Similar content being viewed by others
Abbreviations
- ADA:
-
Adalimumab
- CT:
-
Computed tomography
- CZP:
-
Certolizumab pegol
- DAS:
-
Disease activity score
- ESR:
-
Erythrocyte sedimentation rate
- IFX:
-
Infliximab
- TKA:
-
Total knee arthroplasty
- MRI:
-
Magnetic resonance imaging
- MTX:
-
Methotrexate
- PSL:
-
Prednisolone
- RA:
-
Rheumatoid arthritis
References
Niki Y, Matsumoto H, Otani T, et al. Five types of inflammatory arthritis following total knee arthroplasty. J Biomed Mater Res A. 2007;81:1005–10.
Shinomiya F, Okada M, Hamada Y, et al. Indications of total ankle arthroplasty for rheumatoid arthritis: evaluation at 5 years or more after the operation. Mod Rheumatol. 2003;13:153–9.
Boldt JG, Munzinger UK, Zanetti M, et al. Arthrofibrosis associated with total knee arthroplasty: gray-scale and power Doppler sonographic findings. AJR Am J Roentgenol. 2004;182:337–40.
Roger P, Michael A, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348:36–41.
Ma Y, Li G, Li J, et al. The diagnostic value of superb microvascular imaging (SMI) in detecting blood flow signals of breast lesions: a preliminary study comparing SMI to color doppler flow imaging. Med (Baltim). 2015;94:e1502.
Kawashiri SY, Suzuki T, Nakashima Y, et al. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatol (Oxf). 2014;53:562–9.
Kawashiri SY, Kawakami A, Iwamoto N, et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatol (Oxf). 2011;50:962–5.
Okamoto T, Futani H, Atsui K, et al. Sonographic appearance of fibrous nodules in patellar clunk syndrome: a case report. J Orthop Sci. 2002;7:590–3.
Jacobson JA, van Holsbeeck MT. Musculoskeletal ultrasonography. Orthop Clin North Am. 1998;29:135–67.
Takase K, Ohno S, Takeno M, et al. Simultaneous evaluation of long-lasting knee synovitis in patients undergoing arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology. Clin Exp Rheumatol. 2012;30:85–92.
Gaigneux E, Cormier G, Varin S, et al. Ultrasound abnormalities in septic arthritis are associated with functional outcomes. Joint Bone Spine. 2017.
Emery P, Bingham CO 3rd, Burmester GR, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017;76:96–104.
Koarada S, Tsuboi M, Komine M, et al. Effectiveness of certolizumab pegol in treating rheumatoid arthritis patients with persistent inflamed residual mono- or oligosynovitis resistant to prior TNF-α inhibitors. Case Rep Rheumatol. 2015:348614.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical statements
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from the patient for this report.
Conflict of interest
The authors have no conflicts of interest to report.
About this article
Cite this article
Kawashiri, Sy., Michitsuji, T. & Kawakami, A. Certolizumab pegol was effective for treating residual synovitis after total knee arthroplasty in a patient with rheumatoid arthritis: therapeutic monitoring by ultrasound. J Med Ultrasonics 45, 371–374 (2018). https://doi.org/10.1007/s10396-017-0806-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10396-017-0806-5